Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemo‐ or radiotherapy, or surgery)
Referencias
Additional references
Cochrane Pain, Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. http://papas.cochrane.org/papas‐documents (accessed 22 June 2015)2012.
Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, et al. The impact of chemotherapy‐induced nausea and vomiting on health‐related quality of life. Supportive Care in Cancer 2007;15(2):179‐85.
Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. European Journal of Pharmacology 2014;5(722):48‐54.
Davis MP, Walsh D. Treatment of nausea and vomiting in advanced cancer. Supportive Care in Cancer 2000;8(6):444‐52.
De Oliveira GS, Castro‐Alves LJS, Ahmad S, Kendall MC, McCarthy RJ. Dexamethasone to prevent postoperative nausea and vomiting: An updated meta‐analysis of randomized controlled trials. Anesthesia and Analgesia 2013;116(1):58‐74.
Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T. Symptom control during the last week of life on a palliative care unit. Journal of Palliative Care 1991;7(1):5‐11.
Farr WC. The use of corticosteroids for symptom management in terminally ill patients. American Journal of Hospice Care 1990;7(1):41‐6.
Feyer PC, Stewart Al, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Supportive Care in Cancer 1998;6:253‐60.
Foubert J, Vaessen G. Nausea: the neglected symptom?. European Journal of Oncology Nursing 2005;9:21‐32.
Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist‐based pharmacotherapy. CNS Drugs 2001;21(10):813‐833.
Gannon C, McNamara P. A retrospective observation of corticosteroid use at the end of life in a hospice. Journal of Pain and Symptom Management 2002;24(3):328‐34.
Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far‐advanced cancer. Supportive Care in Cancer 2004;12:432‐40.
Gralla RJ, Osoba D, Kris MG. Recommendations for the use of antiemetics: evidence‐based clinical practice guidelines. Journal of Clinical Oncology 1999;17:2971‐94.
Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Annals of Oncology 2007;18(2):233‐40.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6.
Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S, Portenoy R (Editors). Oxford Textbook of Palliative Care. 4th Edition. Oxford Press, 2009.
Hardy J, Rees E, Ling J, Stone P, Burman R, Feuer D, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliative Medicine 2001;15:3‐8.
Hardy JR, Glare P, Yates Patsy, Mannix KA. Palliation of nausea and vomiting, Section 10.2. In: Cherny N, Fallon M, Kaasa S, Portenoy RK, Currow DC editor(s). Oxford Textbook of Palliative Medicine. 5th Edition. Oxford University Press, 2015.
Harris DG. Nausea and vomiting in advanced cancer. British Medical Bulletin 2010;96:175‐85.
Haywood A, Good P, Khan S, Leupp A, Jenkins‐Marsh S, Rickett K, et al. Corticosteroids for the management of cancer‐related pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD010756.pub2]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration, 2011.
Hursti TJ, Fredrikson M, Steineck G, Borjeson S, Furst CJ, Peterson C. Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. British Journal of Cancer 1993;68:112‐4.
Ioannidis JP, Hesketh Pj, Lau J. Contribution of dexamethasone to control chemotherapy‐induced nausea and vomiting: a meta‐analysis of randomized evidence. Journal of Clinical Oncology 2000;18(19):3409‐22.
Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy‐ naive and previously treated patients. Annals of Oncology 1994;5:253‐8.
Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schünemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;2:81.
Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1998;16:1174‐8.
Laval G, Girardier J, Laussauumiere J, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?. Palliative Medicine 2000;14:3‐10.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W65‐94.
Mantovani G, Maccio A, Massa E, Lai P, Esu S. Cisplatin induces serotonin release from human peripheral blood mononuclear cells of cancer patients and methylprednisolone inhibits this effect. Oncology Reports 1997;4(5):1051‐3.
Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. Journal of Pain and Symptom Management 2004;28:412‐6.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264‐9.
National Cancer Institute. Common Terminology Citeria for Adverse Events (CTCAE) v.4.0. National Institute of Health. Bethesda, Maryland, U.S.A.: National Institute of Health, Department of Health and Human Services, 2010.
Perugia Consensus Conference. Prevention of chemotherapy‐ and radiotherapy‐induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Annals of Oncology 1998;9(8):811‐9.
Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, et al. Nausea still the poor relation in antiemetic therapy? The impact on cancer patient's quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Supportive Care in Cancer 2013;21:735‐48.
Porternoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander‐Klar H, Coyle N, et al. Symptom prevalence, characteristics and distress in a cancer population. Quality of Life Research 1994;3(3):183‐9.
Reuben D. Nausea and vomiting in terminal cancer patients. Archives of Internal Medicine 1986;146(10):2021‐3.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Riechelmann RP, Krzyanowska MK, O'Carrol A, Zimmermann C. Symptom and medication profiles among cancer patients attending a palliative care clinic. Supportive Care in Cancer 2007;15(12):1407‐12.
Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy‐ and radiotherapy‐induced emesis: results of the 2004 Perugia Internation Antiemetic Consensus Conference. Annals of Oncology 2006;17:20‐8.
Smith HS. A receptor‐based paradigm of nausea and vomiting. Journal of Cancer Pain and Symptom Palliation 2005;1(1):11‐23.
Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. Journal of Pain and Symptom Management 2007;34(1):94‐104.
Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 patients. Supportive Care in Cancer 2000;8(3):175‐9.
